NewsBenzinga杰富瑞维持对亨斯迈的“买入”评级，将目标价下调至11美元 杰富瑞维持对亨斯迈的“买入”评级，将目标价下调至11美元 Benzinga 2026.10.02 20:15 (GMT+0) Open on Benzinga Other news If You Invested $100 In Flowserve Stock 5 Years Ago, You Would Have This Much Today $1000 Invested In Cogent Biosciences 5 Years Ago Would Be Worth This Much Today Tonix Pharmaceuticals Says Dr. Reddy's Files ANDA With Paragraph IV Patent Certification For Generic TONMYA On Oct 1; Paragraph IV Certification Challenges Four TONMYA Patents Listed In FDA Orange Book; Co Intends To Enforce TONMYA Intellectual Property... NeoVolta Files Prospectus Related To The Resale Of Up To 1.5M Shares Of Common Stock Selling Stockholders If You Invested $100 In Republic Services Stock 10 Years Ago, You Would Have This Much Today Novo Provides Update On The Denecimig Biologics License Application In The US; The FDA Has Informed Novo That The BLA Review Of Denecimig For The Treatment Of Haemophilia A Is Still Ongoing; The FDA Has Not Communicated A New Timeline For Regulatory...
Tonix Pharmaceuticals Says Dr. Reddy's Files ANDA With Paragraph IV Patent Certification For Generic TONMYA On Oct 1; Paragraph IV Certification Challenges Four TONMYA Patents Listed In FDA Orange Book; Co Intends To Enforce TONMYA Intellectual Property...
NeoVolta Files Prospectus Related To The Resale Of Up To 1.5M Shares Of Common Stock Selling Stockholders
Novo Provides Update On The Denecimig Biologics License Application In The US; The FDA Has Informed Novo That The BLA Review Of Denecimig For The Treatment Of Haemophilia A Is Still Ongoing; The FDA Has Not Communicated A New Timeline For Regulatory...
